Search clinical trials for: MK0557

Total 103 results

Merck Sharp & Dohme LLC

Completed

A 2-Year Study of an Investigational Drug in Obese Patients (0557-011)

Obesity
Merck Sharp & Dohme LLC

Completed

A Study to Determine the Effects of MK0557 in Obese Subjects (0557-006)(COMPLETED)

Obesity
Merck Sharp & Dohme LLC

Completed

A 1-Year Study of an Investigational Drug in Obese Patients (0557-012)(COMPLETED)

Obesity
Merck Sharp & Dohme LLC

Completed

MK0557 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0557-027)

Schizophrenia | Paranoid Schizophrenia
Merck Sharp & Dohme LLC

Completed

MK0457 in Patients With Leukemia (0457-003)

Myelodysplastic Syndromes | Myelogenous Leukemia, Chronic | Chronic Myelogenous Leukemia in Blast Crisis | Lymphocytic Leukemia, B Cell, Acute
Merck Sharp & Dohme LLC

Terminated

A Phase II Study of MK0457 in Patients With T315I Mutant CML and Ph+All (0457-008)

Leukemia
Merck Sharp & Dohme LLC

Terminated

A Phase IIA Study of MK0457 in Patients With Cancer of the Lung (0457-006)

Carcinoma, Non-Small-Cell Lung
Merck Sharp & Dohme LLC

Completed

Efficacy of MK0557 in Combination With Sibutramine or Orlistat (0557-015)(COMPLETED)

Obesity
Merck Sharp & Dohme LLC

Terminated

MK0457 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Colorectal Cancer and Other Advanced Solid Tumors (0457-001)

Colorectal Cancer | Advanced Solid Tumors
Merck Sharp & Dohme LLC

Completed

A Clinical Study to Determine Biomarkers of Response to a Gamma Secretase Inhibitor

Healthy
Vyne Therapeutics Inc.

Completed

Safety and Efficacy of MK0594 to Treat Overactive Bladder (0594-003)

Overactive Bladder | Urinary Incontinence
Merck Sharp & Dohme LLC

Terminated

Treatment of Sarcopenia in Post-Hip Fracture Patients (0677-032)

Hip Fracture

Germany, Norway, Spain, Sweden, United Kingdom
Merck Sharp & Dohme LLC

Completed

MK0524 Seasonal Allergic Rhinitis Study (0524-005)(COMPLETED)

Seasonal Allergies
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety Study of MK0359 in Patients With Arthritis (0359-017)

Rheumatoid Arthritis
Merck Sharp & Dohme LLC

Completed

Study of MK0677 for the Treatment of Alzheimer's Disease (0677-030)(COMPLETED)

Alzheimer's Disease
Merck Sharp & Dohme LLC

Completed

A Study of MK0359 in Patients With Chronic Asthma (0359-013)

Asthma
Merck Sharp & Dohme LLC

Terminated

Safety and Preliminary Efficacy of MK0759 in Postherpetic Neuralgia (PHN)(0759-004)

Neuralgia, Postherpetic
Merck Sharp & Dohme LLC

Completed

A Study of MK0359 in Patients With Chronic Obstructive Pulmonary Disease (COPD)(0359-016)

Pulmonary Disease, Chronic Obstructive
Merck Sharp & Dohme LLC

Terminated

MK0767 in Type 2 Diabetes (0767-012)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Terminated

Study A - MK0767 Monotherapy Study

Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC

Completed

A Study of MK0777 in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-020)

Anxiety Disorders
Merck Sharp & Dohme LLC

Terminated

MK0767 and Sulfonylurea Combination Study (0767-027)

Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC

Terminated

Dyslipidemia in Type 2 Diabetes (0767-034)

Dyslipidemia | Diabetes Mellitus, Type II
Merck Sharp & Dohme LLC

Terminated

MK0354 Clinical Efficacy and Tolerability Study (0354-004)

Dyslipidemia
Merck Sharp & Dohme LLC

Terminated

MK0952 in Patients With Mild-to-Moderate Alzheimer's Disease (0952-004)(COMPLETED)

Alzheimer's Disease
Merck Sharp & Dohme LLC

Terminated

A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013)

Myelodysplastic Syndromes | Chronic Lymphocytic Leukemia | Leukemia, Lymphoblastic, Acute, T-cell | Myelogenous Leukemia
Merck Sharp & Dohme LLC

Completed

A Notch Signalling Pathway Inhibitor for Patients With Advanced Breast Cancer (0752-014)

Advanced Breast Cancer | Other Solid Tumors
Merck Sharp & Dohme LLC

Completed

A Study of MK0777 Gel Extrusion Module (GEM) in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-019)

Generalized Anxiety Disorder
Vyne Therapeutics Inc.

Terminated

A Study of MK0594 in Patients With Alcohol Dependence (0594-020)

Alcohol Dependence
Merck Sharp & Dohme LLC

Completed

Treatment of Cognitive Impairment in Men With Schizophrenia (MK5757-005)(COMPLETED)

Schizophrenia
Merck Sharp & Dohme LLC

Completed

Treatment of Patients With Anxiety Disorder (0777-022)

Generalized Anxiety Disorder
Merck Sharp & Dohme LLC

Terminated

Placebo Controlled Metformin and Sulfonylurea Combination Study in Patients With Type 2 Diabetes (0767-025)

Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC

Terminated

MK0767 and Metformin Combination Study (0767-028)

Diabetes Mellitus
Merck Sharp & Dohme LLC

Terminated

MK0767 Glipizide Comparator Cardiac Safety Study (0767-018)

Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC

Terminated

MK0767 Added to Insulin Therapy in Patients With Type 2 Diabetes (0767-030)

Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC

Terminated

A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED)

Chronic Myelogenous Leukemia | Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of an Investigational Drug in Human Immunodeficiency Virus (HIV)-Infected Patients Failing Current Antiretroviral Therapies (0518-005)(COMPLETED)

HIV Infections | Acquired Immunodeficiency Syndrome
Organon and Co

Completed

A Research Study to Evaluate the Safety and Effectiveness of MK0217 to Prevent and Treat Bone Loss (0217-193)(COMPLETED)

Osteoporosis
Merck Sharp & Dohme LLC

Completed

GEM 1.5 mg b.i.d. to 4.5 mg b.i.d. Versus Lorazepam in GAD (0777-026)

Anxiety Disorder
Organon and Co

Completed

A Research Study to Test the Effectiveness of MK0217 in Patients With Paget's Bone Disease (0217-206)(COMPLETED)

Paget's Disease of Bone
Merck Sharp & Dohme LLC

Terminated

Study MK0767 and Metformin in Type 2 Diabetic Patients (0767-020)

Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC

Terminated

Efficacy and Tolerability of MK0533 in Patients With Type 2 Diabetes (0533-005)

Diabetes Mellitus Type 2
Merck Sharp & Dohme LLC

Completed

A Study to Investigate the Influence of MK0859 on Blood Pressure (MK-0859-012)(COMPLETED)

Ambulatory Blood Pressure
Merck Sharp & Dohme LLC

Terminated

MK0859 Dose-Ranging Study (0859-003)

Hypercholesterolemia | Mixed Hyperlipemia
Merck Sharp & Dohme LLC

Completed

A Study of MK0859 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia (MK-0859-011)(COMPLETED)

Hypercholesterolemia | Hyperlipidemia
Organon and Co

Completed

Open Label Study Evaluating The Use Of Combination Therapy Of Ezetimibe And Statins In Patients With Dyslipidemia In Colombia (0653-141)(COMPLETED)

Lipid Metabolism Disorder
Organon and Co

Completed

Randomized Parallel Group Trial Of The Efficacy And Safety Of Ezetimibe With A Statin Versus Statin Dose Doubling In Patients With Persistent Primary Hypercholesterolemia (0653-152)(COMPLETED)

Hypercholesterolemia
Merck Sharp & Dohme LLC

Completed

MK0524 Asthma POC Study (0524-008)(COMPLETED)

Asthma
Merck Sharp & Dohme LLC

Completed

Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019) (DEFINE)

Coronary Heart Disease (CHD) | CHD Risk-Equivalent Disease
Merck Sharp & Dohme LLC

Terminated

MK0767 in Metabolic Syndrome-Dyslipidemia (0767-016)

Metabolic X Syndrome Dyslipidemia

3

Subscribe